ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical Response"

  • Abstract Number: 347 • 2017 ACR/ARHP Annual Meeting

    Disease Burden at One Academic Rheumatology Routine Care Setting Is Similar in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) at First Visit but Significantly Greater in OA at a 6-Month Follow-up Visit

    Jacquelin R. Chua1, Shakeel M. Jamal1, Isabel Castrejón1, Najia Shakoor1, Anne-Marie Malfait2, Joel A. Block2 and Theodore Pincus2, 1Division of Rheumatology, Rush University Medical Center, Chicago, IL, 2Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Osteoarthritis commonly is regarded as less severe and less debilitating than RA. However, limited data are available for direct comparison of OA versus RA,…
  • Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting

    Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity

    Nathan den Broeder1, Lieke Tweehuysen1, Noortje van Herwaarden1, Thomas Vogl2, F.H.J. van den Hoogen1, Rogier Thurlings3 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2University of Muenster, Muenster, Germany, 3Rheumatology, Radboudumc, Nijmegen, Netherlands

    Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…
  • Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting

    No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients

    Lieke Tweehuysen1, Nathan den Broeder1, Leo .A.B. Joosten2, Thomas Vogl3, F.H.J. van den Hoogen4, Rogier Thurlings5 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 3University of Muenster, Muenster, Germany, 4Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 5Rheumatology, Radboudumc, Nijmegen, Netherlands

    Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…
  • Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting

    ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort

    Janet E. Pope1, Emmanouil Rampakakis2, Mohammad Movahedi3, Angela Cesta3, John S. Sampalis4 and Claire Bombardier3, 1Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 2JSS Medical Research, Montreal, QC, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4McGill University, Montreal, QC, Canada

    ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…
  • Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Ketti Terry4, Kenneth Kwok5, Sander Strengholt6, Ryan DeMasi7 and Lisy Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
  • Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting

    48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin

    David Wofsy1, David A. Isenberg2, Frédéric A. Houssiau3, Mary Anne Dooley4, Neil Solomons5 and Simrat Randhawa6, 1Rheumatology, UCSF, San Francisco, CA, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 4UNC Kidney Centre, Chapel Hill, NC, 5Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 6Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
  • Abstract Number: 1206 • 2017 ACR/ARHP Annual Meeting

    Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders

    J-Y Reginster, Bone Cartilage Unit, University of Liege, Liege, Belgium

    Background/Purpose: In addition to the assessment of the two co-primary endpoints – pain and function – regulatory agencies recommend the use of responder rates in…
  • Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

    Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms…
  • Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium

    Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

    Takayuki Kishi1, William Warren-Hicks2, Michael Ward3, Nastaran Bayat1, Lan Wu1, Gulnara Mamyrova4, Ira N. Targoff5, Frederick Miller1, Lisa G. Rider1 and the Childhood Myositis Heterogeneity Study Group, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, 2EcoStat, Inc., Mebane, NC, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, 5VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose:  Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood.  We examined a large JDM registry for predictors of excellent Rx…
  • Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting

    Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway

    Guro Løvik Goll1,2, Inge C Olsen3, Kristin K Jorgensen4, Merete Lorentzen5, Nils Bolstad6, Espen A. Haavardsholm7, Knut EA Lundin8, Cato Mork9, Jorgen Jahnsen4, Tore K Kvien3 and the NOR-SWITCH study group, 1Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway, 8Dept of gastroenterology, Rikshospitalet, Oslo, Norway, 9Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

      Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of  spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA),  Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting

    Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis

    Teresa Jurado1, Chamaida Plasencia-Rodriguez2, Ana Martínez3, Victoria Navarro-Compán4, Eva Olariaga-Merida5, Diana Peiteado6, Alejandro Villalba6, Gema Bonilla6, Cristina Diego7, Alejandro Balsa2 and Dora Pascual-Salcedo8, 1Immunology, University Hospital La Paz, Madrid, Spain, 2Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, 3Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, 4Rheumatology, University Hospital La Paz, Madrid, Spain, 5Immunlogy, University Hospital La Paz, Madrid, Spain, 6Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 7Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, 8Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain

    Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
  • Abstract Number: 2538 • 2016 ACR/ARHP Annual Meeting

    Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis

    Christopher J. Swearingen, Jessica Poon, Hannah Bernstein and Yusuf Yazici, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
  • Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting

    Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

    J. Antonio Avina-Zubieta1, Andrew Chow2, Philip Baer3, John Kelsall4, Proton Rahman5, Jacqueline Stewart6, Boulos Haraoui7, Michel Zummer8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Francois Nantel11, Karina Maslova12, Cathy Tkaczyk13, Brendan Osborne13 and Allen J Lehman12, 1Arthritis Research Canada, Richmond, BC, Canada, 2Credit Valley Rheumatology, Mississauga, ON, Canada, 3Independent Rheumatology Practice, Scarborough, ON, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 6Penticton Regional Hospital, Penticton, BC, Canada, 7University of Montreal, Montreal, QC, Canada, 8Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 1119 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
  • Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting

    Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual

    Hironari Hanaoka1, Hidehiro Yamada2, Tomofumi Kiyokawa3, Harunobu Iida1, Takeshi Suzuki1, Yoshioki Yamasaki4, Seido Ooka5, Hiroko Nagafuchi3, Takahiro Okazaki3, Daisuke Ichikawa6, Sayuri Shirai6, Yugo Shibagaki7, Junki Koike8 and Shoichi Ozaki3, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, 3Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 4Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, 5Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, 8Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
  • Abstract Number: 2920 • 2016 ACR/ARHP Annual Meeting

    The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

    Maaike Boonstra1, Annemarie L. Dorjée1, Koen D. Quint2, Tom W.J. Huizinga1, Hans U. Scherer3 and Jeska K. de Vries-Bouwstra1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Dermatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Open-label studies provided evidence for possible efficacy of rituximab (RTX) in systemic sclerosis (SSc). Previously, we reported on a randomized placebo-controlled clinical trial in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology